Apellis Pharmaceuticals, Inc. — Director's Dealing 2019

Sep 25, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2019-09-23

Reporting Person: Deschatelets Pascal (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-23	Common Stock	S	20758	$25.068	Disposed	924986	Direct
2019-09-23	Common Stock	S	100	$25.53	Disposed	924886	Direct
2019-09-24	Common Stock	S	20307	$24.561	Disposed	904579	Direct
2019-09-24	Common Stock	S	1295	$24.958	Disposed	903284	Direct

Footnotes

F1: Sale originated from established 10b5-1 trading plan.

F2: Average Sale Price within $1. Min $24.53-Max $25.47

F3: Average Sale Price within $1. Min $23.91-Max $24.90

F4: Average Sale Price within $1. Min $24.91-Max $25.06